Bayer is aiming to extend the approval of its cancer drug Nubeqa with new study data.

The drug achieved the primary objective in a pivotal Phase 3 clinical trial in patients with metastatic hormone-sensitive prostate cancer, the pharmaceutical and agricultural company announced on Wednesday. In combination with a standard treatment, androgen deprivation therapy, Nubeqa significantly prolonged radiographic progression-free survival. Bayer plans to submit the data from the study to the relevant regulatory authorities worldwide and is aiming to expand the use of the drug. This also promises additional sales.

Nubeqa was Bayer's fourth best-selling pharmaceutical product last year with revenues of EUR 869 (2022: 466) million. It is already approved for two forms of prostate cancer. The Leverkusen-based company believes that the cancer drug, which was launched on the market in 2019, has a peak sales potential of more than three billion euros.

(Report by Patricia Weiß, edited by Ralf Banser. If you have any queries, please contact our editorial team at berlin.newsroom@thomsonreuters.com (for politics and the economy) or frankfurt.newsroom@thomsonreuters.com (for companies and markets).)